# Why Lilly's Weight Loss Pill Isn't a Peptide **Author:** Philipp D. Dubach | **Published:** April 9, 2026 **Categories:** Medicine **Keywords:** Foundayo vs oral Wegovy, orforglipron vs oral semaglutide, oral GLP-1 weight loss pill 2026, oral semaglutide bioavailability SNAC, GLP-1 market size obesity 2030, Foundayo orforglipron FDA approval 2026, Foundayo weight loss pill price, Novo Nordisk vs Eli Lilly GLP-1 2026, oral weight loss pill GLP-1, small molecule GLP-1 receptor agonist, oral semaglutide Wegovy pill 25mg, GLP-1 manufacturing cost COGS, semaglutide patent expiry 2031 biosimilar, oral GLP-1 pipeline aleniglipron VK2735 amycretin, GLP-1 adherence persistence discontinuation, anti-obesity medication market expansion, Jevons Paradox statin analogy GLP-1 ## Key Takeaways - Oral semaglutide has ~1% bioavailability, meaning each pill destroys 99% of its active ingredient, requiring 280x more API than the equivalent injection - Eli Lilly's Foundayo (orforglipron) is a small molecule, not a peptide, bypassing the oral delivery problem that cost Novo decades and $1.8B - The GLP-1 market hit $70B in 2025; oral pills are expected to expand the market, not cannibalize injections (statin precedent: 197% user growth) - Current GLP-1 penetration is under 5% of eligible US adults vs. 35%+ for statins, implying massive expansion ahead --- >Novo Nordisk spent decades and $1.8 billion learning how to get a peptide past the gut. Eli Lilly looked at the same problem and decided to skip it entirely. Your gastrointestinal tract is a 30-foot disassembly line for proteins. Acid denatures them, pepsin cleaves them, trypsin finishes the job, and the mucus layer blocks whatever survives. Sean Geiger's excellent [history of oral peptides](https://seangeiger.substack.com/p/a-brief-history-of-oral-peptides) traces the full arc: the first attempt at oral insulin was in 1922. Over a hundred years and thirteen companies later, no oral insulin exists. Novo Nordisk spent decades and $1.8 billion acquiring the technology to get around this problem. The result, approved in December 2025 as [oral Wegovy for obesity](https://www.endocrinologyadvisor.com/news/fda-approves-oral-wegovy-for-weight-management/), is a pill that destroys 99% of its own active ingredient before the remaining fraction reaches the bloodstream. The oral 25mg daily dose uses roughly 280x more semaglutide than the equivalent weekly injection. This is the best that peptide oral delivery can do. Eli Lilly decided to skip it entirely, building Foundayo, a small molecule oral obesity drug that isn't a peptide at all. That divergence in approach will determine who captures the majority of a market that [Goldman Sachs projects](https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market) at $100+ billion by 2030 and that [J.P. Morgan estimates](https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs) will reach 30 million US users within five years. ## Oral semaglutide Sean Geiger's [history of oral peptides](https://seangeiger.substack.com/p/a-brief-history-of-oral-peptides) traces the science well. The technology that makes oral semaglutide possible is SNAC (salcaprozate sodium), a permeation enhancer developed by Emisphere Technologies starting in the 1990s. Novo partnered with Emisphere in 2007 and [acquired the company outright in 2020](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916472). SNAC does three things simultaneously: it buffers local stomach pH to suppress pepsin, prevents semaglutide from clumping into inactive oligomers, and temporarily fluidizes gastric cell membranes so the drug can cross. The [EMA's public assessment report](https://www.ema.europa.eu/en/documents/assessment-report/rybelsus-epar-public-assessment-report_en.pdf) puts the resulting bioavailability at roughly 0.4 to 1%. The [FDA label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf) confirms: the vast majority of each dose is destroyed. This creates a problem that's easy to state and hard to solve. If you need 280x more API per equivalent dose, your manufacturing cost structure looks nothing like the injectable. A [Yale/King's College study published in JAMA](https://www.fastcompany.com/91071415/your-1000-per-month-ozempic-costs-5-to-make-says-study) found injectable semaglutide costs $0.89 to $4.73 per month to manufacture at the API level. Scale that by 280x and you get oral API costs somewhere in the range of $770 to $1,460 per year, according to [The Medicine Maker's January 2026 analysis](https://themedicinemaker.com/issues/2026/articles/january/oral-glp-1s-won-t-win-on-convenience-they-ll-win-on-cmc/). Still below the selling price. But the margin compression is real, and SNAC itself is a costly excipient. Oral semaglutide bioavailability trap: 280x more API per dose than injectable Wegovy, SNAC achieves only 1% absorption, while Eli Lilly Foundayo bypasses the peptide oral delivery problem SNAC is also oddly specific. [Geiger notes](https://seangeiger.substack.com/p/a-brief-history-of-oral-peptides) that Novo tried it with liraglutide, a closely related GLP-1 analog, and it failed because liraglutide forms oligomers that SNAC can't break apart. After over three decades of work, exactly two FDA-approved oral peptide drugs using permeation enhancers exist: Rybelsus/oral Wegovy (SNAC) and Mycapssa (oral octreotide for acromegaly, a different enhancer called TPE). That's the entire commercial output of the field. ## Foundayo: Lilly's structural advantage Eli Lilly's [orforglipron](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head), approved by the FDA on April 1, 2026 under the brand name [Foundayo](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill), is not an oral peptide. It's a non-peptide small molecule GLP-1 receptor agonist that activates the same receptor through a different mechanism. Discovered by Chugai Pharmaceutical and licensed by Lilly in 2018, orforglipron requires no SNAC, no fasting window, no cold chain storage, and is manufactured through standard chemical synthesis rather than solid-phase peptide synthesis. The bioavailability problem doesn't apply because the molecule was designed from the ground up to survive the gut. The clinical data backs this up. In [ACHIEVE-3](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head) (1,698 patients with type 2 diabetes, 52 weeks), orforglipron at 12mg and 36mg was superior to oral semaglutide on both HbA1c reduction and weight loss: the first head-to-head victory over Novo's oral product. In [ATTAIN-2](https://www.appliedclinicaltrialsonline.com/view/eli-lilly-oral-glp1-orforglipron-efficacy-safety-injectable-phaseiii-trial) (obesity with type 2 diabetes), orforglipron delivered 10.5% weight loss at 72 weeks versus 2.2% on placebo. And in [ATTAIN-MAINTAIN](https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after), patients who switched from injectable Wegovy or Mounjaro to oral orforglipron maintained their weight within 0.9 kg over 52 weeks. A pill that holds the gains of an injection. Lilly [submitted the NDA](https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial) with a priority review voucher and received [FDA approval on April 1, 2026](https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill), the fastest approval of a new molecular entity since 2002. Foundayo is available starting at $149 per month for self-pay patients, with savings card prices as low as $25 per month. The company is investing [$6.5 billion in a dedicated oral manufacturing facility](https://cen.acs.org/pharmaceuticals/pharmaceutical-chemicals/Lilly-pour-65-billion-GLP/103/web/2025/09) and $27 billion total in US manufacturing capacity. Foundayo orforglipron vs oral Wegovy semaglutide comparison: peptide plus SNAC approach versus small molecule across bioavailability, manufacturing cost, fasting requirements, and ACHIEVE-3 clinical results ## $70 billion duopoly and its widening crack The gap is widening. Combined GLP-1 revenue from Novo and Lilly hit roughly $70 billion in 2025. But the composition shifted. Lilly's tirzepatide franchise (Mounjaro plus Zepbound) [generated $36.5 billion](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026), with Zepbound alone growing 175% year-over-year. Novo's semaglutide franchise came in around $33 billion, with growth decelerating to roughly 10% in constant exchange rates. [Lilly's US market share hit 57%](https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html) by mid-2025, up from 41% a year earlier. Novo's share fell to 43%. The stock market has been ruthless in pricing this shift. Novo trades at roughly $48 per ADR share, down 65% from its June 2024 peak of $142, a loss exceeding $350 billion in market cap. The company [guided for a 5 to 13% revenue decline in 2026](https://www.cnbc.com/2026/02/04/eli-lilly-novo-nordisk-earnings-glp1-market.html), driven by patent expirations in Canada, Brazil, and China, plus pricing pressure from the Trump administration's drug pricing framework. CagriSema, Novo's most important pipeline asset, [disappointed twice](https://www.biopharmadive.com/news/novo-nordisk-cagrisema-obesity-drug-study-results/735854/): 22.7% weight loss in REDEFINE 1 (below the company's own 25% guidance) and 15.7% in REDEFINE 2. [Novo's stock plunged 20% on the first readout alone](https://www.cnbc.com/2024/12/20/novo-nordisk-shares-plunge-22percent-after-cagrisema-obesity-drug-trial-results.html). Lilly, by contrast, [guided 2026 revenue at $80 to $83 billion](https://www.fiercepharma.com/pharma/even-pricing-headwinds-eli-lilly-expects-sales-continue-surge-2026), a 25% increase, and [trades near $1,044](https://finance.yahoo.com/quote/LLY/) with a market cap around $1 trillion, the first pharma company to reach that level. Forward P/E: roughly 30x versus Novo's 12.5x. That 2.4x valuation premium reflects a simple thesis: Lilly has the better drug (Zepbound [showed 47% greater weight loss](https://www.nejm.org/doi/full/10.1056/NEJMoa2416394) than Wegovy in the SURMOUNT-5 head-to-head), the better oral pipeline, and the longer patent runway (tirzepatide patents extend into the mid-2030s versus [semaglutide's core US patent expiring December 2031](https://www.trademarkia.com/news/patents/when-does-the-ozempic-patent-expire), with biosimilar competition likely following shortly after). Novo Nordisk vs Eli Lilly GLP-1 duopoly: Lilly at 2.4x Novo forward PE, 57% US market share, revenue and patent runway comparison The Hims & Hers saga sits at the chaotic edge of all this. HIMS [launched a $49 per month compounded oral semaglutide pill](https://finance.yahoo.com/news/nvo-lly-stocks-slide-hims-142700745.html) on February 5, 2026, using unproven liposomal technology with no published bioavailability data. Within four days, [HHS had referred the company to the DOJ](https://markets.financialcontent.com/stocks/article/marketminute-2026-2-9-the-glp-1-gold-rush-hits-a-wall-novo-nordisk-sues-hims-and-hers-as-fda-crackdown-triggers-20-stock-crash), Novo had [filed a patent infringement lawsuit](https://www.gurufocus.com/news/8587678/novo-nordisk-nvo-shares-plunge-amid-competition-from-hims-hers-hims), and HIMS had suspended the product. Novo's CEO alleged independent testing of compounded samples showed impurity levels as high as 86%. What happens when the incentive to undercut $1,000-per-month pricing collides with the actual difficulty of making peptide drugs work orally. ## Does Oral Delivery Commoditize GLP-1 Does oral delivery commoditize GLP-1s, or does it expand the market so dramatically that even with pricing pressure, the opportunity grows Early evidence already supports the expansion thesis: [Novo's oral Wegovy pill uptake is running roughly 10x higher](https://www.cnbc.com/2026/04/07/novo-nordisks-wegovy-pill-launch-draws-new-wave-of-patients-to-glp-1s.html) than the original injectable Wegovy launch, drawing in new patients rather than converting existing injection users. The statin precedent is the strongest data point we have. After generic atorvastatin launched in 2011, total statin use [expanded from 31 million to 92 million Americans](https://pmc.ncbi.nlm.nih.gov/articles/PMC10203693/) by 2019, a **197% increase**. Total prescription volume grew 77%. The per-unit price collapsed, but total market volume more than compensated. Updated clinical guidelines, lower copays, and reduced patient resistance combined to pull in millions of people who would never have started therapy at the original price and delivery format. Current penetration is absurdly low: [fewer than 5% of eligible US adults](https://icer.org/wp-content/uploads/2025/04/Affordable-Access-to-GLP-1-Obesity-Medications-_-ICER-White-Paper-_-04.09.2025.pdf) are on anti-obesity medication therapy, against 104 million with obesity. At statin-like penetration rates of 35% or higher, that's a 5 to 10x expansion. Persistence data reinforces the point: only [32% of obesity patients persist at one year and 15% at two years](https://www.primetherapeutics.com/documents/d/primetherapeutics/prime-therapeutics_glp-1-therapy-to-treat-obesity-among-members-without-diabetes_three-year-persistence). Side effects account for 43.7% of discontinuation, financial barriers for 30.9%. Adherence collapses when the friction is high. An oral weight loss pill that's cheaper, eliminates the injection barrier, and has no fasting restrictions (orforglipron) attacks all three. ## Oral GLP-1 pipeline The rest of the oral GLP-1 pipeline is worth tracking but the outcomes are uncertain. [Viking's oral VK2735](https://www.prnewswire.com/news-releases/viking-therapeutics-announces-positive-top-line-results-from-phase-2-venture-oral-dosing-trial-of-vk2735-tablet-formulation-in-patients-with-obesity-302533355.html) showed rapid weight loss in Phase 2 (up to 12.2% at 13 weeks) but a [38% discontinuation rate](https://www.biopharmadive.com/news/viking-oral-obesity-drug-results-study-discontinuationsdata-dropout/758019/) at the highest dose sent the stock down 37%. [Structure Therapeutics' aleniglipron](https://ir.structuretx.com/news-releases/news-release-details/structure-therapeutics-reports-positive-topline-data-access) posted 15.3% placebo-adjusted weight loss at 36 weeks in Phase 2b, competitive numbers with no plateau, and has $786 million in cash to fund Phase 3. [Pfizer's danuglipron was killed](https://www.statnews.com/2025/04/14/pfizer-discontinue-danuglipron-glp-1-obesity-liver-toxicity/) by liver toxicity in April 2025, the second Pfizer oral GLP-1 failure. [Terns Pharmaceuticals also exited](https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2) after weak Phase 2 data and liver enzyme elevations. Behind them, Novo's oral amycretin, a GLP-1/amylin dual agonist, enters Phase 3 in 2026 and could offer best-in-class weight loss if the oral formulation holds up. Oral small molecule GLP-1 development has a meaningful failure rate, and Foundayo's clean safety profile across multiple Phase 3 trials is not something I'd assume the next entrant can replicate. Oral GLP-1 pipeline 2026: Foundayo approved, aleniglipron Phase 3, VK2735 Phase 2, oral amycretin Phase 3, with Pfizer and Terns programs killed by liver toxicity The thing that makes this market so interesting is that almost every important variable is in motion at the same time: form factor (injection to pill), pricing structure ($1,000 per month to $149 to potentially lower), patent protection (expiring internationally, holding domestically), competitive dynamics (Novo decelerating, Lilly sprinting with Foundayo, Hims imploding), and the macro question of Medicare coverage. I'm more confident in the structural thesis, that oral GLP-1s expand the market through a Jevons-like dynamic, than I am in picking the right entry point for any individual stock. But if forced to bet on which company is best positioned for that expansion, the answer seems clear. Lilly built the molecule that doesn't need to fight the gut. Novo built one that fights and mostly loses. At 30x forward earnings for Lilly and 12.5x for Novo, there's a version of this where Novo is the contrarian value play and Lilly is priced for perfection. I don't think that's the right framing. I think Novo is cheap because it has structural problems, the worst kind of cheap, and Lilly is expensive because it has structural advantages, the best kind of expensive. --- ## Frequently Asked Questions ### How does oral semaglutide work if only 1% is absorbed? Only 0.4 to 1% of oral semaglutide reaches the bloodstream, meaning over 99% is destroyed in the gut. The permeation enhancer SNAC (salcaprozate sodium) temporarily buffers stomach acid and fluidizes gastric cell membranes, allowing a small fraction of the peptide to cross. The oral 25mg daily dose requires approximately 280x more active ingredient than the equivalent weekly injection. ### Is Foundayo better than the oral Wegovy pill for weight loss? Foundayo (orforglipron) beat oral semaglutide on both HbA1c reduction and weight loss in the ACHIEVE-3 head-to-head trial at 52 weeks. However, cross-trial comparisons suggest oral Wegovy 25mg may produce greater weight loss (roughly 14% vs 12%), while Foundayo has the convenience advantage of no fasting requirements. Foundayo also had higher gastrointestinal discontinuation rates. ACHIEVE-3 compared against semaglutide 7mg and 14mg doses, not the higher 25mg Wegovy pill dose approved for obesity. ### What is the current GLP-1 market size and who is winning? The GLP-1 market reached approximately $70 billion in combined Novo Nordisk and Eli Lilly revenue in 2025. Lilly's tirzepatide franchise (Mounjaro + Zepbound) generated $36.5 billion, surpassing Novo's semaglutide franchise at roughly $33 billion. Lilly holds 57% US GLP-1 market share as of mid-2025, up from 41% a year earlier. ### Will oral GLP-1 pills expand the obesity market or replace injections? Oral pills will likely expand the market rather than cannibalize injections. The statin precedent is instructive: after generic atorvastatin launched in 2011, total statin use expanded from 31 million to 92 million Americans by 2019, a 197% increase. Current GLP-1 penetration is under 5% of eligible US adults versus 35%+ for statins, implying large expansion as oral delivery lowers barriers to initiation, improves adherence, and reduces discontinuation. ### When does semaglutide's patent expire? Semaglutide's core US patent expires December 5, 2031, with formulation patents extending to 2033. International patents in Canada, China, India, and Brazil are expiring in 2026, opening the door to generic and biosimilar competition outside the US. Tirzepatide patents extend into the mid-2030s, giving Eli Lilly a structural advantage in the oral GLP-1 market. ### What oral GLP-1 weight loss pills are FDA approved in 2026? Two oral GLP-1 pills are FDA approved for weight loss: Novo Nordisk's oral Wegovy pill (semaglutide 25mg), approved December 2025 and launched January 2026, and Eli Lilly's Foundayo (orforglipron), approved April 1, 2026. Behind them, Novo's oral amycretin enters Phase 3 in 2026, Structure Therapeutics' aleniglipron targets mid-2026 Phase 3 start, and Viking Therapeutics' VK2735 oral showed promising Phase 2 data but had high discontinuation rates. ### How much does Foundayo cost per month? Foundayo starts at $149 per month for the lowest dose for self-pay patients. Eligible commercially insured patients may pay as little as $25 per month with the Foundayo savings card. Eligible Medicare Part D individuals may be able to get Foundayo for $50 per month beginning July 2026. The oral Wegovy pill is priced at $149 to $299 per month depending on dose. --- *Philipp D. Dubach — [http://philippdubach.com/](http://philippdubach.com/) — 2026*